by Allison Kennedy | May 10, 2023 | Citation Alerts
Tempo-iMG™ was cited in cell.com in a study that investigated HIV-1 integration in the unexplored microglia reservoir that gives rise to continued HIV replication in infected cells. Scientists used Tempo-iMG™ human iPSC-derived microglia to determine that CTCF, an...
by Karen O'Hanlon Cohrt | Sep 24, 2023 | Disease Models
In our last few liver articles, we highlighted the urgent need for new models and treatments for non-alcoholic steatohepatitis (NASH), and looked at the potential for human liver organoids to not only model disease, but also to test new drugs for safety and efficacy....
by Karen O'Hanlon Cohrt | Jul 18, 2023 | Disease Models
The lack of approved treatments for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatosis (NASH) is largely explained by the shortcomings of cellular models used to unravel disease mechanisms, identify and validate new drug targets, and screen...
by Angela L. Huang | Apr 10, 2019 | News
SAN FRANCISCO, CA —Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived products and affiliated cell-based services in the following categories:...
by Angela L. Huang | Mar 15, 2023 | News
SAN FRANCISCO, CA —Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following...
